Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - tacrolimus -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tacrolimus -

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - roxithromycin 150mg;   - coated tablet - 150 mg - active: roxithromycin 150mg   excipient: colloidal silicon dioxide glucose hyprolose hypromellose magnesium stearate maize starch povidone propylene glycol purified talc titanium dioxide water - adults roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections caused by or likely to be caused by susceptible micro-organisms: · upper respiratory tract infection - acute pharyngitis, tonsillitis and sinusitis · dental infections · lower respiratory tract infection - acute bronchitis; acute exacerbations of chronic bronchitis and community acquired pneumonia · skin and skin structure infections · non-gonococcal urethritis. children roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis, acute tonsillitis and impetigo. appropriate culture and sensitivity tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - roxithromycin 300mg;   - coated tablet - 300 mg - active: roxithromycin 300mg   excipient: colloidal silicon dioxide glucose hyprolose hypromellose magnesium stearate maize starch povidone propylene glycol purified talc titanium dioxide water

New Zealand - English - Medsafe (Medicines Safety Authority)

research associates ltd - tacrolimus 0.5mg - capsule - 0.5 mg - active: tacrolimus 0.5mg excipient: croscarmellose sodium gelatin hypromellose iron oxide yellow lactose monohydrate magnesium stearate purified water titanium dioxide - primary immunosuppression in liver, kidney, pancreas, kidney-pancreas, lung or heart allograft recipients and rescue use in liver, kidney or other solid organ (heart, lung, pancreas or kidney-pancreas) transplantation, that has either failed conventional immunosuppressive agents, or where such agents are producing intolerable side effects.

New Zealand - English - Medsafe (Medicines Safety Authority)

research associates ltd - tacrolimus 1mg - capsule - 1 mg - active: tacrolimus 1mg excipient: croscarmellose sodium hypromellose lactose monohydrate magnesium stearate - primary immunosuppression in liver, kidney, pancreas, kidney-pancreas, lung or heart allograft recipients and rescue use in liver, kidney or other solid organ (heart, lung, pancreas or kidney-pancreas) transplantation, that has either failed conventional immunosuppressive agents, or where such agents are producing intolerable side effects.

New Zealand - English - Medsafe (Medicines Safety Authority)

research associates ltd - tacrolimus 5mg - capsule - 5 mg - active: tacrolimus 5mg excipient: croscarmellose sodium gelatin hypromellose iron oxide red lactose monohydrate magnesium stearate opacode white s-1-18086 titanium dioxide water - primary immunosuppression in liver, kidney, pancreas, kidney-pancreas, lung or heart allograft recipients and rescue use in liver, kidney or other solid organ (heart, lung, pancreas or kidney-pancreas) transplantation, that has either failed conventional immunosuppressive agents, or where such agents are producing intolerable side effects.

New Zealand - English - Medsafe (Medicines Safety Authority)

research associates ltd - tacrolimus 5 mg/ml - concentrate for infusion - 5 mg/ml - active: tacrolimus 5 mg/ml excipient: ethanol hydrogenated castor oil nitrogen - primary immunosuppression in liver, kidney, pancreas, kidney-pancreas, lung or heart allograft recipients and rescue use in liver, kidney or other solid organ (heart, lung, pancreas or kidney-pancreas) transplantation, that has either failed conventional immunosuppressive agents, or where such agents are producing intolerable side effects.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tacrolimus, quantity: 5 mg - capsule, modified release - excipient ingredients: lactose monohydrate; titanium dioxide; hypromellose; sodium lauryl sulfate; iron oxide red; magnesium stearate; iron oxide yellow; ethylcellulose; gelatin; hyprolose; butan-1-ol; purified water; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - advagraf xl is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tacrolimus, quantity: 1 mg - capsule, modified release - excipient ingredients: hypromellose; iron oxide yellow; gelatin; sodium lauryl sulfate; titanium dioxide; ethylcellulose; iron oxide red; magnesium stearate; lactose monohydrate; hyprolose; butan-1-ol; purified water; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - advagraf xl is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.